Ear Disorders
Also known as: Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Ear Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is an ear disorder? An ear disorder is any condition that changes or harms the shape or structure of your ear.
- 2 Real-world patient consensus: Diagnostic registry H61.009: Ear Disorders is managed within ENT & Hearing (aka Disorder).
- 3 Typical cash cost range: Workup highlights for Ear Disorders (H61.009): hearing protection/amplification [Ear Disorders H61.009].
- 4 Top reported side effects / signs: Follow-up benchmark in Ear Disorders: maintaining Periodontal Pocket Depth in Ear Disorders (H61.009: & Bleeding Index) within Probing <= 3 mm without bleeding (H61.009).
Ask our AI Specialists anything about Ear Disorders
What Is Ear Disorders?
What is an ear disorder? An ear disorder is any condition that changes or harms the shape or structure of your ear. This can include abnormal ear shapes you're born with, injuries that change your ear's shape, and a growth on or in the ear. Your ear has three main parts, and each one plays a different role in helping you hear: Outer ear. The part you see and the ear canal. It catches sound and sends them to your eardrum. Middle ear. When sound reaches your eardrum, it vibrates. These vibrations move through three small bones, called ossicles, that carry them further into your ear. Inner ear. Changes vibrations into nerve signals your brain understands as sound.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Ear Disorders (code H61.009) is oropharyngeal tonsillar or in Ear Disorders (H61.009: laryngeal mucosal inflammation), Cross-referenced with NIH MeSH (Ear Diseases), which Ear, Nose, Throat & Oral Health clinicians address while surveilling Periodontal Pocket Depth in Ear Disorders (H61.009: & Bleeding Index) (Probing <= 3 mm without bleeding (H61.009)).
Common Symptoms & Clinical Signs
- • Outer ear. The part you see and the ear canal. It catches sound and sends them to your eardrum
- • Inner ear. Changes vibrations into nerve signals your brain understands as sound. It also helps you keep your balance
- • Presentation of Ear Disorders (H61.009): acute earache, sore in Ear Disorders (H61.009: throat with painful)
- • Secondary Ear Disorders clinical sign: episodic spinning vertigo in Ear Disorders (H61.009: accompanied by fluctuating)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Ear Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H61.009 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Ear, Nose, Throat & Oral Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Periodontal Pocket Depth in Ear Disorders (H61.009: & Bleeding Index) | Probing <= 3 mm without bleeding (H61.009) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pure-Tone Audiometry & in Ear Disorders (H61.009: Tympanometry) | Thresholds <= 20 dB HL; normal middle-ear pressure (H61.009) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Ear Disorders
Treatment selection for Ear Disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ear Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Comparative efficacy and acceptability of anxiolytic drugs for the treatment of: What a 28,637-Participant Study Found This network meta-analysis provides a unique comparison of the efficacy and acceptability of anxiolytics. European archives of psychiatry and clinical neuroscience • 2026-06-15 • Meta-Analysis | N = 28,637 | 99/100 | PMID 40788541 ↗ |
| New Insights on Benefits and safety of etifoxine versus alprazolam in generalized anxiety with: What a 260-Participant Study Found Treatment-emergent AEs were mild and observed in 10% and 7.7% of patients in the Etifoxine and Alprazolam groups, respectively. Journal of anxiety disorders • 2026-04-15 • Phase III Randomized Trial | N = 260 | 93/100 | PMID 41763071 ↗ |
| New Insights on Predictors of response to pharmacotherapy in children and adolescents with: What a 599-Participant Study Found Allocation to active drugs, female sex, and early improvement may predict treatment response to pharmacotherapy among children and adolescents with psychiatric disorders. Neuropsychopharmacology reports • 2022-12-15 • Randomized Controlled Trial | N = 599 | 93/100 | PMID 36330567 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Luspatercept offers rapid and durable benefits by improving anemia-related symptoms and quality of life in patients with NTDT. European journal of haematology • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41857682 ↗ |
| Can This Approach Help? Inside the Latest Research on A post hoc analysis of linaclotide in children patients with functional In children with FC and comorbid NDD, linaclotide 72 µg once daily was associated with improved constipation outcomes, high staying on track with medication, and a well-tolerated safety profile, similar to that seen in the... Journal of pediatric gastroenterology and nutrition • 2026-07-15 • Phase III Randomized Trial | N = 25 | 88/100 | PMID 41913506 ↗ |
Ear Disorders Patient Community & “People Like Me” Threads
Filter Ear Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.